Gastrointestinal microbiota composition predicts peripheral inflammatory state during treatment of human tuberculosis
Matthew F Wipperman, Shakti K Bhattarai, Charles Kyriakos Vorkas, Venkata Suhas Maringati, Ying Taur, Laurent Mathurin, Katherine McAulay, Stalz Charles Vilbrun, Daphie Francois, James Bean, Kathleen F Walsh, Carl Nathan, Daniel W Fitzgerald, Michael S Glickman, Vanni Bucci, Matthew F Wipperman, Shakti K Bhattarai, Charles Kyriakos Vorkas, Venkata Suhas Maringati, Ying Taur, Laurent Mathurin, Katherine McAulay, Stalz Charles Vilbrun, Daphie Francois, James Bean, Kathleen F Walsh, Carl Nathan, Daniel W Fitzgerald, Michael S Glickman, Vanni Bucci
Abstract
The composition of the gastrointestinal microbiota influences systemic immune responses, but how this affects infectious disease pathogenesis and antibiotic therapy outcome is poorly understood. This question is rarely examined in humans due to the difficulty in dissociating the immunologic effects of antibiotic-induced pathogen clearance and microbiome alteration. Here, we analyze data from two longitudinal studies of tuberculosis (TB) therapy (35 and 20 individuals) and a cross sectional study from 55 healthy controls, in which we collected fecal samples (for microbiome analysis), sputum (for determination of Mycobacterium tuberculosis (Mtb) bacterial load), and peripheral blood (for transcriptomic analysis). We decouple microbiome effects from pathogen sterilization by comparing standard TB therapy with an experimental TB treatment that did not reduce Mtb bacterial load. Random forest regression to the microbiome-transcriptome-sputum data from the two longitudinal datasets reveals that renormalization of the TB inflammatory state is associated with Mtb pathogen clearance, increased abundance of Clusters IV and XIVa Clostridia, and decreased abundance of Bacilli and Proteobacteria. We find similar associations when applying machine learning to peripheral gene expression and microbiota profiling in the independent cohort of healthy individuals. Our findings indicate that antibiotic-induced reduction in pathogen burden and changes in the microbiome are independently associated with treatment-induced changes of the inflammatory response of active TB, and the response to antibiotic therapy may be a combined effect of pathogen killing and microbiome driven immunomodulation.
Trial registration: ClinicalTrials.gov NCT02684240.
Conflict of interest statement
M.F.W. is currently an employee and shareholder of Regeneron Pharmaceuticals, Inc. M.S.G. reports consulting fees and equity in Vedanta Biosciences, Inc., consulting fees from Takeda, and is on the SAB of PRL-NYC. V.B. is supported by a Sponsored Research Agreement from Vedanta Biosciences, Inc. The remaining authors declare no competing interests.
Figures
References
- Martin CR, Osadchiy V, Kalani A, Mayer EA. The brain-gut-microbiome axis. Cell Mol. Gastroenterol. Hepatol. 2018;6:133–148. doi: 10.1016/j.jcmgh.2018.04.003.
- Atarashi K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500:232–236. doi: 10.1038/nature12331.
- Atarashi K, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337–341.
- Tanoue T, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565:600–605. doi: 10.1038/s41586-019-0878-z.
- Vorkas CK, et al. Mucosal-associated invariant and gammadelta T cell subsets respond to initial Mycobacterium tuberculosis infection. JCI Insight. 2018;3:e121899. doi: 10.1172/jci.insight.121899.
- Campbell C, et al. Extrathymically generated regulatory t cells establish a niche for intestinal border-dwelling bacteria and affect physiologic metabolite balance. Immunity. 2018;48:1245–1257 e1249. doi: 10.1016/j.immuni.2018.04.013.
- Levan, S. R. et al. Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance. Nat. Microbiol.4, 1851–1861 (2019).
- Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–141. doi: 10.1016/j.cell.2014.03.011.
- Ryan FJ, et al. Changes in the composition of the gut microbiota and the blood transcriptome in preterm infants at less than 29 weeks gestation diagnosed with bronchopulmonary dysplasia. mSystems. 2019;4:e00484–00419. doi: 10.1128/mSystems.00484-19.
- Grigg JB, Sonnenberg GF. Host-microbiota interactions shape local and systemic inflammatory diseases. J. Immunol. 2017;198:564–571. doi: 10.4049/jimmunol.1601621.
- Wang Z, Arat S, Magid-Slav M, Brown JR. Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets. BMC Syst. Biol. 2018;12:3. doi: 10.1186/s12918-017-0524-z.
- Kaforou M, et al. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med. 2013;10:e1001538. doi: 10.1371/journal.pmed.1001538.
- Zak DE, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387:2312–2322. doi: 10.1016/S0140-6736(15)01316-1.
- Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010;466:973–977. doi: 10.1038/nature09247.
- Lesho E, et al. Transcriptional responses of host peripheral blood cells to tuberculosis infection. Tuberculosis. 2011;91:390–399. doi: 10.1016/j.tube.2011.07.002.
- Ottenhoff TH, et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE. 2012;7:e45839. doi: 10.1371/journal.pone.0045839.
- Bloom CI, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE. 2013;8:e70630. doi: 10.1371/journal.pone.0070630.
- Cliff JM, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J. Infect. Dis. 2013;207:18–29. doi: 10.1093/infdis/jis499.
- Singhania A, et al. A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. Nat. Commun. 2018;9:2308. doi: 10.1038/s41467-018-04579-w.
- Aljayyoussi G, et al. Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Sci. Rep. 2017;7:502–502. doi: 10.1038/s41598-017-00529-6.
- Namasivayam S, et al. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome. 2017;5:71. doi: 10.1186/s40168-017-0286-2.
- Wipperman MF, et al. Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci. Rep. 2017;7:10767. doi: 10.1038/s41598-017-10346-6.
- Faith JJ, Ahern PP, Ridaura VK, Cheng J, Gordon JI. Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci. Transl. Med. 2014;6:220ra211. doi: 10.1126/scitranslmed.3008051.
- Geva-Zatorsky N, et al. Mining the human gut microbiota for immunomodulatory organisms. Cell. 2017;168:928–943 e911. doi: 10.1016/j.cell.2017.01.022.
- Shigyo K, et al. Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2013;57:2834–2837. doi: 10.1128/AAC.02542-12.
- Walsh KF, et al. Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis. Antimicrob. Agents Chemother. 2020;64:e01956-19. doi: 10.1128/AAC.01956-19.
- Harausz EP, et al. Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture. Tuberculosis. 2016;98:92–96. doi: 10.1016/j.tube.2016.03.002.
- Wagner, B. D. et al. On the use of diversity measures in longitudinal sequencing studies of microbial communities. Front. Microbiol.9, 1037 (2018).
- Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47–e47. doi: 10.1093/nar/gkv007.
- Parada Venegas, D. et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol.10, 277 (2019).
- Heinken A, et al. Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease. Microbiome. 2019;7:75. doi: 10.1186/s40168-019-0689-3.
- Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol. Rev. 2017;279:90–105. doi: 10.1111/imr.12563.
- Rivera-Chávez F, et al. Depletion of butyrate-producing clostridia from the gut microbiota drives an aerobic luminal expansion of Salmonella. Cell Host Microbe. 2016;19:443–454. doi: 10.1016/j.chom.2016.03.004.
- Kelly CJ, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial hif augments tissue barrier function. Cell Host Microbe. 2015;17:662–671. doi: 10.1016/j.chom.2015.03.005.
- Reese AT, et al. Antibiotic-induced changes in the microbiota disrupt redox dynamics in the gut. Elife. 2018;7:e35987. doi: 10.7554/eLife.35987.
- Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102.
- Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. Preprint at bioRxiv 060012 (2019).
- Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–425.
- Glickman MS, Cox JS, Jacobs WR., Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell. 2000;5:717–727. doi: 10.1016/S1097-2765(00)80250-6.
- Krzywinska, E. & Stockmann, C. Hypoxia, metabolism and immune cell function. Biomedicines6, 56 (2018).
- Palmer NP, et al. Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease. PLoS ONE. 2019;14:e0222952–e0222952. doi: 10.1371/journal.pone.0222952.
- Knox NC, Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiome as a target for IBD treatment: are we there yet? Curr. Treat. Options Gastroenterol. 2019;17:115–126. doi: 10.1007/s11938-019-00221-w.
- Magurran, A. E. Measuring Biological Diversity. (John Wiley & Sons, 2013).
- Haran JP, et al. Alzheimer’s disease microbiome is associated with dysregulation of the anti-inflammatory P-glycoprotein pathway. MBio. 2019;10:e00632-19. doi: 10.1128/mBio.00632-19.
- Johnstone IM, Titterington DM. Statistical challenges of high-dimensional data. Philos. Trans. A Math. Phys. Eng. Sci. 2009;367:4237–4253.
- Altmann A, Tolosi L, Sander O, Lengauer T. Permutation importance: a corrected feature importance measure. Bioinformatics. 2010;26:1340–1347. doi: 10.1093/bioinformatics/btq134.
- Apley, D. W. & Zhu, J. Visualizing the effects of predictor variables in black box supervised learning models. J. R. Statis. Soc.82, 1059–1086 (2016).
- Collins MD, et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J. Syst. Bacteriol. 1994;44:812–826. doi: 10.1099/00207713-44-4-812.
- Lopetuso LR, Scaldaferri F, Petito V, Gasbarrini A. Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog. 2013;5:23–23. doi: 10.1186/1757-4749-5-23.
- Garrett WS, et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe. 2010;8:292–300. doi: 10.1016/j.chom.2010.08.004.
- Seishima J, et al. Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biol. 2019;20:252. doi: 10.1186/s13059-019-1879-9.
- Peled JU, et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 2020;382:822–834. doi: 10.1056/NEJMoa1900623.
- Freedberg DE, et al. Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. Intensive Care Med. 2018;44:1203–1211. doi: 10.1007/s00134-018-5268-8.
- Zeng MY, Inohara N, Nuñez G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol. 2017;10:18–26. doi: 10.1038/mi.2016.75.
- Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 2013;14:7. doi: 10.1186/1471-2105-14-7.
- Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA. 2011;108(Suppl 1):4554–4561. doi: 10.1073/pnas.1000087107.
- Lavelle A, et al. Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. Microbiome. 2019;7:111. doi: 10.1186/s40168-019-0725-3.
- Morgun A, et al. Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut. 2015;64:1732–1743. doi: 10.1136/gutjnl-2014-308820.
- Mayer-Barber KD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014;511:99–103. doi: 10.1038/nature13489.
- Pirofski, L.-A. & Casadevall, A. Antimicrobial therapy in the context of the Damage-response framework: the prospect of optimizing therapy by reducing host damage. Antimicrob. Agents Chemother.64, 1800-01819 (2019).
- Namasivayam S, Sher A, Glickman MS, Wipperman MF. The microbiome and tuberculosis: early evidence for cross talk. MBio. 2018;9:e01420-18. doi: 10.1128/mBio.01420-18.
- Arpaia N, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451–455. doi: 10.1038/nature12726.
- Gold MC, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol. 2010;8:e1000407. doi: 10.1371/journal.pbio.1000407.
- Skelly AN, Sato Y, Kearney S, Honda K. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat. Rev. Immunol. 2019;19:305–323. doi: 10.1038/s41577-019-0144-5.
- Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Nat. Rev. Microbiol. 2019;17:497–511. doi: 10.1038/s41579-019-0213-6.
- Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case–control and two-gate designs in diagnostic accuracy studies. Clin. Chem. 2005;51:1335–1341. doi: 10.1373/clinchem.2005.048595.
- Diacon AH, et al. Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens. Tuberculosis. 2014;94:148–151. doi: 10.1016/j.tube.2013.12.002.
- Harris PA, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 2009;42:377–381. doi: 10.1016/j.jbi.2008.08.010.
- Callahan BJ, et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods. 2016;13:581–583. doi: 10.1038/nmeth.3869.
- Dupnik KM, et al. Blood transcriptomic markers of Mycobacterium tuberculosis load in sputum. Int. J. Tuberc. Lung Dis. 2018;22:950–958. doi: 10.5588/ijtld.17.0855.
- Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012;29:15–21. doi: 10.1093/bioinformatics/bts635.
- Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–930.
- Hartley SW, Mullikin JC. QoRTs: a comprehensive toolset for quality control and data processing of RNA-Seq experiments. BMC Bioinforma. 2015;16:224–224. doi: 10.1186/s12859-015-0670-5.
- Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–112. doi: 10.1038/nature08460.
Source: PubMed